尽管hVIVO正在进行COVID-19研究,并且市值为1.299亿英,但其股价下跌6.8%,至19.10英. hVIVO's stock drops 6.8% to £19.10, despite working on COVID-19 studies and having a £129.95 million market cap.

hVIVO是一家对疫苗和抗病毒药物进行人类挑战临床试验的公司,其存货在星期四下降了6.8%,交易额为19.10英镑(0.24美元)。 hVIVO, a company that conducts human challenge clinical trials for vaccines and antivirals, saw its stock drop by 6.8% on Thursday, trading at £19.10 ($0.24). 该公司服务于大型制药、生物技术和政府组织。 The company serves big pharma, biotech, and government organizations. 尽管有所下降,但VIVO的市场上限为1.2995亿英镑,并正在努力为COVID-19开发一个人类挑战研究模型。 Despite the decline, hVIVO has a market cap of £129.95 million and is working on developing a human challenge study model for COVID-19.